ARA-290 10mg (10 vials/kit): Innate Repair Receptor Agonist for Neuroprotective Research

ARA-290 (also known as Cibinetide or Pyroglutamate Helix B Surface Peptide, $\text{pHBSP}$) is a synthetic 11-amino-acid peptide derived from the spatial structure of erythropoietin ($\text{EPO}$). Exhibiting the chemical sequence $\text{pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH}$, ARA-290 was rationally designed to selectively target the Innate Repair Receptor ($\text{IRR}$)—a heteroreceptor complex composed of erythropoietin receptor and common beta receptor subunit monomers ($\text{EPOR-}\beta\text{cR}_2$). Sourcing ARA-290 10mg (10 vials/kit) provides neurobiologists, pain researchers, and cell signaling laboratories with a high-purity analytical reagent engineered to investigate tissue protection, peripheral nerve regeneration, and anti-inflammatory signaling cascades.

In classical hematology, native erythropoietin binds homodimeric erythropoietin receptors ($\text{EPOR}_2$) on erythroid progenitor cells to stimulate red blood cell production (erythropoiesis). However, tissue protection and anti-inflammatory signaling occur through the distinct $\text{EPOR-}\beta\text{cR}_2$ Innate Repair Receptor heteromer, which requires lower binding affinity but responds to tissue distress signals. ARA-290 binds selectively to the $\text{IRR}$ without activating the classical homodimeric $\text{EPOR}_2$. Consequently, ARA-290 triggers downstream neuroprotective, anti-apoptotic, and anti-inflammatory pathways without increasing hematocrit, blood viscosity, or thromboembolic risk in preclinical models.

Maintaining exact stoichiometry and chemical purity is critical for quantitative cell culture assays and neuropathic pain models. The ARA-290 10mg (10 vials/kit) configuration supplies a total yield of 100mg active peptide material (10mg per vial) distributed across ten individual USP Type I borosilicate glass vials. Freeze-dried under sterile vacuum conditions, each vial contains a uniform, highly stable lyophilized powder cake. This multi-vial kit format enables laboratory personnel to reconstitute only the working volume needed for active experimental trials, preserving remaining kit stock in deep-freeze stasis to protect against thermal degradation and hydrolytic cleavage.

Innate Repair Receptor Activation, Anti-Inflammatory Signaling, and Technical Profile

The primary scientific value of ARA-290 10mg (10 vials/kit) stems from its non-erythropoietic mechanism and selective tissue-protective signaling profile:

• Selective Innate Repair Receptor ($\text{IRR}$) Agonism: Binds specifically to the $\text{EPOR-}\beta\text{cR}_2$ heteroreceptor complex, activating tissue protection mechanisms without binding classical homodimeric $\text{EPOR}_2$.

• Non-Erythropoietic Profile: Stimulates cellular repair and survival pathways without elevating red blood cell mass, hemoglobin levels, or systemic blood viscosity.

• Neuroprotection & Peripheral Nerve Regeneration: Promotes small nerve fiber repair ($\text{A-}\delta$ and $\text{C}$ fibers) and suppresses neuropathic signaling in preclinical models of diabetic neuropathy and sarcoidosis.

• Nuclear Factor-$\kappa\text{B}$ ($\text{NF-}\kappa\text{B}$) Inhibition: Blocks activation of the $\text{NF-}\kappa\text{B}$ pathway, downregulating pro-inflammatory cytokine secretion ($\text{TNF-}\alpha$, $\text{IL-1}\beta$, $\text{IL-6}$) in ischemia-reperfusion and inflammatory tissue models.

• Anti-Apoptotic Cellular Survival: Activates downstream Akt and $\text{STAT3}$ signaling cascades, inhibiting caspase activation and preserving tissue integrity under hypoxic or ischemic stress.

• Ultra-High Chemical Purity ($\ge$99.0%): Manufactured via automated Solid-Phase Peptide Synthesis ($\text{SPPS}$) and purified using preparative High-Performance Liquid Chromatography ($\text{HPLC}$) to ensure complete removal of deletion sequences and synthesis byproducts.

Reconstitution Guidelines, Laboratory Storage Standards, and Quality Protocols

Achieving reproducible, publication-grade results when working with ARA-290 10mg (10 vials/kit) requires strict adherence to standardized laboratory preparation and climate-controlled storage protocols.

Perform all reconstitution procedures inside a certified Class II Biosafety Cabinet:

1. Temperature Balancing: Allow the frozen ARA-290 vial to adjust to ambient room temperature prior to solvent introduction to eliminate moisture condensation inside the glass container.

2. Septum Sanitization: Remove the protective plastic flip-cap and thoroughly wipe the synthetic rubber stopper with a fresh 70% isopropyl alcohol pad. Allow the surface to dry completely.

3. Slow Diluent Addition: Using a sterile syringe equipped with a fine-gauge needle, draw the required volume of Bacteriostatic Water (0.9% benzyl alcohol), Sterile Normal Saline (0.9% NaCl), or Phosphate-Buffered Saline (PBS). Direct the liquid stream against the inner glass wall so it trickles slowly over the lyophilized cake.

4. Gentle Hydration: Allow the diluent to fully hydrate the powder cake for 2 minutes. Gently roll the vial between your palms or swirl in smooth circular motions until clear. Never vortex or shake vigorously, as high-shear agitation can shear peptide bonds and induce protein foaming.

5. Micro-Aliquot Strategy: For multi-week testing protocols, divide reconstituted liquid into sterile, single-use microcentrifuge tubes under aseptic conditions to prevent atmospheric oxidation and eliminate repeated freeze-thaw cycles.

Batch Quality Documentation & Traceability: Every production lot of ARA-290 10mg (10 vials/kit) undergoes third-party analytical testing. High-Performance Liquid Chromatography (HPLC) chromatograms confirm component purity exceeding 99.0%, while Electrospray Ionization Mass Spectrometry (ESI-MS) confirms precise theoretical molecular mass. Each shipment includes a batch-specific Certificate of Analysis (COA) documenting chemical purity, residual solvent analysis, heavy metal screens, and bacterial endotoxin levels (<0.05 EU/mg) to satisfy institutional compliance requirements.

Strict Regulatory & Research Compliance Statement: ARA-290 10mg (10 vials/kit) is produced, packaged, and distributed exclusively for in vitro laboratory research, academic experimentation, chemical synthesis, and preclinical research. ARA-290 10mg (10 vials/kit) is strictly not intended, formulated, or approved for human or animal consumption, therapeutic medical treatment, clinical diagnostic work, or cosmetic applications. All handling must be conducted by certified research personnel operating within equipped laboratory facilities in compliance with OSHA workplace safety regulations and institutional biosafety protocols.